Royal Bank Of Canada Has Lowered Expectations for Intuitive Surgical (NASDAQ:ISRG) Stock Price

Intuitive Surgical (NASDAQ:ISRG) had its price objective dropped by investment analysts at Royal Bank Of Canada from $575.00 to $550.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical equipment provider’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 25.57% from the stock’s current price.

A number of other brokerages have also weighed in on ISRG. Evercore set a $430.00 price target on shares of Intuitive Surgical in a research note on Monday, July 6th. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Wednesday. Leerink Partners lowered their price objective on shares of Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating for the company in a research report on Friday, July 17th. Oppenheimer reissued an “outperform” rating on shares of Intuitive Surgical in a research report on Wednesday. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Twenty-five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $498.72.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $438.00 on Wednesday. Intuitive Surgical has a fifty-two week low of $328.57 and a fifty-two week high of $603.88. The stock has a market capitalization of $154.74 billion, a PE ratio of 50.17, a price-to-earnings-growth ratio of 3.27 and a beta of 1.46. The business’s 50-day simple moving average is $392.96 and its 200-day simple moving average is $409.06.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The business had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same period in the previous year, the firm earned $2.40 EPS. Intuitive Surgical’s quarterly revenue was up 21.7% compared to the same quarter last year. On average, research analysts expect that Intuitive Surgical will post 8.87 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In related news, EVP Mark Brosius sold 77 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total value of $28,918.89. Following the sale, the executive vice president owned 881 shares of the company’s stock, valued at approximately $330,877.17. This trade represents a 8.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $374.44, for a total value of $407,765.16. Following the completion of the sale, the vice president directly owned 1,026 shares in the company, valued at approximately $384,175.44. This represents a 51.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,370 shares of company stock valued at $4,891,989 over the last ninety days. Company insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

A number of large investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in Intuitive Surgical by 3.3% during the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after purchasing an additional 116,292 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Intuitive Surgical in the second quarter valued at $1,335,753,000. Amundi grew its position in Intuitive Surgical by 8.6% in the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock valued at $1,119,448,000 after purchasing an additional 193,096 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Intuitive Surgical by 95.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after buying an additional 1,027,475 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Intuitive Surgical by 13.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,745,008 shares of the medical equipment provider’s stock valued at $804,431,000 after buying an additional 211,237 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 results exceeded expectations: Revenue rose 21.7% year over year to $3.05 billion, above the approximately $2.91 billion consensus, while adjusted earnings reached $3.00 per share versus estimates of roughly $2.61–$2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained healthy: Worldwide procedures increased approximately 15%, including 14% growth for da Vinci procedures and 31% for Ion procedures. Intuitive placed 546 robotic systems, up from 427 a year earlier. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Potentially broader adoption: Intuitive plans to extend instrument life and reduce per-procedure costs in 2027. Although this could pressure near-term revenue per procedure, management views it as a way to make robotic surgery more affordable and expand the installed base. Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
• Neutral Sentiment: Leasing is supporting placements: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it can also make Intuitive’s returns more dependent on future procedure volume. Does Leasing Make Growth More Durable or More Capital Intensive?
• Negative Sentiment: Large antitrust settlement charge hurt GAAP earnings: Intuitive recorded a $450 million pre-tax charge, or $347 million after tax, related to a proposed settlement. GAAP net income fell to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier; court approval is still required. Antitrust Settlement Charge Overshadows Strong Q3 Growth
• Negative Sentiment: 2026 procedure-growth guidance was narrowed to 14%–15%: The tighter outlook, along with planned pricing actions targeting a 3%–5% reduction in instrument and accessory costs per procedure, raised concerns that growth and margins may moderate. Intuitive Narrows 2026 Procedure Growth Outlook

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.